2026-10-01T12:05:57.000Z · 2 days ago Azitra completes Cohort 1 in Phase 1/2 clinical trial evaluating ATR04-484
Oct 1, 2026, 8:00 AM EDT · 2 days ago Azitra, Inc. Advances ATR-04 Phase 1/2 Clinical Trial to Cohort 2 Following Safety Review Committee Clearance
Sep 8, 2026, 8:00 AM EDT · 25 days ago Azitra, Inc. to Present at the H.C. Wainwright 28th Annual Global Investment Conference
Aug 21, 2026, 8:00 AM EDT · 6 weeks ago Azitra, Inc. Regains Compliance with NYSE American Continued Listing Standards
Aug 12, 2026, 5:00 PM EDT · 7 weeks ago Azitra, Inc. Announces Q2 2026 Results and Provides Business Updates
2026-07-29T18:05:54.000Z · 2 months ago Azitra building multi market microbial engineering platform, CEO says
2026-07-29T18:05:50.000Z · 2 months ago Azitra says Phase 1/2 ATR 04 trial remains on track for topline data this year
2026-07-29T18:05:45.000Z · 2 months ago CEO says breadth of Azitra’s platform opens multiple attractive markets
2026-07-15T14:30:18.000Z · 2 months ago Azitra announces results from two ex vivo human skin tissue studies
Jul 15, 2026, 10:10 AM EDT · 2 months ago Azitra, Inc. Announces Breakthough Repeat Dose and Anti-Wrinkle Ex Vivo Results for ATR-COSF Program, Demonstrating Increased Distribution and Elasticity
Jun 17, 2026, 8:00 AM EDT · 3 months ago Azitra, Inc. CEO Issues Letter to Shareholders Detailing Strategic Reorientation Initiatives and Outlook for 2026 and Beyond
Jun 4, 2026, 4:05 PM EDT · 4 months ago Azitra Announces Adjournment of 2026 Annual Meeting and Information for Reconvened Meeting
May 27, 2026, 4:30 PM EDT · 4 months ago Azitra Announces Intention to Adjourn Annual Meeting and Reconvene Annual Meeting
2026-05-21T21:00:49.000Z · 4 months ago Azitra files to sell 255.7M shares of common stock for holders
May 13, 2026, 8:30 AM EDT · 4 months ago Azitra, Inc. Announces Q1 2026 Results and Provides Business Updates
May 6, 2026, 8:00 AM EDT · 5 months ago Azitra, Inc. Announces New U.S. Patent Protecting ATR-12 Program
Apr 28, 2026, 8:02 AM EDT · 5 months ago Azitra, Inc. Announces Poster Presentation at ASGCT 2026 Highlighting ATR-01 Program for Ichthyosis Vulgaris
Mar 19, 2026, 1:13 PM EDT · 6 months ago Azitra Announces Pricing of Private Placement Financing of up to Approximately $10.5 Million with up to an Additional Approximately $20.9 Million
Mar 13, 2026, 5:15 PM EDT · 6 months ago Azitra Receives Notice of Non-Compliance from NYSE American and Makes NYSE American Section 610(b) Public Announcement
Mar 5, 2026, 4:30 PM EST · 7 months ago Azitra, Inc. Announces Cancellation of 2026 Special Meeting of Stockholders
Feb 27, 2026, 5:30 PM EST · 7 months ago Azitra, Inc. Announces Full Year 2025 Results and Provides Business Updates
2026-02-24T13:12:53.000Z · 7 months ago Azitra adds MD Anderson Cancer Center as site for Phase 1/2 skin rash trial
Feb 24, 2026, 8:00 AM EST · 7 months ago Azitra, Inc. Announces Addition of MD Anderson Cancer Center as Clinical Site for Phase 1/2 Trial of ATR-04 Targeting EGFRi-Associated Skin Rash
Feb 6, 2026, 4:15 PM EST · 7 months ago Azitra Announces Adjournment of Special Meeting and Information for Reconvened Special Meeting
Jan 7, 2026, 8:00 AM EST · 8 months ago Azitra, Inc. to Present at Biotech Showcase Alongside the J.P. Morgan Annual Healthcare Conference
Dec 17, 2025, 4:10 PM EST · 9 months ago Azitra Receives Notice of Acceptance of the Listing Standards Compliance Plan from NYSE American
2025-12-10T21:16:02.000Z · 9 months ago Azitra files to sell 38.9M shares of common stock for holders
2025-11-24T14:20:36.000Z · 10 months ago Azitra prices 4.69M share private placement at 32c per share
Nov 24, 2025, 9:00 AM EST · 10 months ago Azitra, Inc. Announces Pricing of $1.5 Million Private Placement Priced At a Premium To Market Under NYSE Rules
Nov 12, 2025, 5:15 PM EST · 10 months ago Azitra, Inc. Announces Q3 2025 Results and Provides Business Updates
2025-11-07T11:10:47.000Z · 11 months ago Azitra says report of $44M registered direct offering is false
Nov 7, 2025, 6:00 AM EST · 11 months ago Azitra, Inc. Addresses False Report Regarding Sale of Securities
2025-10-20T12:10:25.000Z · 11 months ago Azitra to present preclinical progress for its ATR-01 program
Oct 20, 2025, 8:02 AM EDT · 11 months ago Azitra, Inc. Announces Positive Preclinical Data for ATR-01 Program, Designed to Treat Ichthyosis Vulgaris
Sep 4, 2025, 8:10 AM EDT · 1 year ago Azitra, Inc. to Present at the H.C. Wainwright 27th Annual Global Investment Conference
Aug 27, 2025, 8:10 AM EDT · 1 year ago Azitra, Inc. Announces First Patient Dosed in Phase 1/2 Trial for ATR-04 Program Targeting Oncology Patients with EGFRi-Associated Rash
Aug 11, 2025, 5:00 PM EDT · 1 year ago Azitra, Inc. Announces Q2 2025 Results and Provides Business Updates
Jun 17, 2025, 8:02 AM EDT · 1 year ago Azitra Reports Promising Safety Data from Phase 1b Trial in Netherton Syndrome
Jun 10, 2025, 8:33 AM EDT · 1 year ago Azitra, Inc. Announces Presentation at the 2025 BIO International Convention
May 28, 2025, 8:33 AM EDT · 1 year ago Azitra, Inc. Announces Presentation at ASCO 2025 Highlighting Clinical Trial Investigating ATR-04 for EGFRi-Associated Rash
May 14, 2025, 4:05 PM EDT · 1 year ago Azitra, Inc. to Present Abstract at American Society of Gene and Cell Therapy Highlighting Phase 1/2 Study Targeting Cancer Therapy-Associated Rash
May 13, 2025, 5:06 PM EDT · 1 year ago Azitra, Inc. Announces Q1 2025 Results and Provides Business Updates
Apr 24, 2025, 4:05 PM EDT · 1 year ago Azitra Announces Share Purchase Agreement for up to $20 Million in Partnership with Alumni Capital to Fund Clinical Pipeline
Feb 24, 2025, 8:30 AM EST · 1 year ago Azitra, Inc. Announces Full Year 2024 Financial Results and Provides Business Updates
Feb 4, 2025, 2:20 PM EST · 1 year ago Azitra Announces Pricing of $930.0 Thousand Registered Direct Offering of Common Stock
Jan 15, 2025, 8:30 AM EST · 1 year ago Azitra Announces Pricing of $1.5 Million Public Offering of Common Stock
Nov 12, 2024, 5:05 PM EST · 1 year ago Azitra, Inc. Announces Q3 2024 Financial Results and Provides Business Updates
Oct 11, 2024, 9:00 AM EDT · 1 year ago Azitra to Participate in the 2024 Maxim Healthcare Virtual Summit
Sep 24, 2024, 8:00 AM EDT · 2 years ago Azitra, Inc. Announces Late-Breaking Presentation at the European Academy of Dermatology and Venereology Congress
Sep 18, 2024, 9:00 AM EDT · 2 years ago Azitra Receives Fast Track Designation for ATR-04 for Skin Rash from EGFR Inhibitors
Sep 6, 2024, 4:30 PM EDT · 2 years ago Azitra to Present at the H.C. Wainwright 26th Annual Global Investment Conference
Aug 28, 2024, 8:30 AM EDT · 2 years ago Azitra Announces First Patient Dosed in Phase 1b Trial of ATR-12 for Netherton Syndrome